UK markets open in 1 hour 33 minutes

Astellas Pharma Inc. (ALPMY)

OTC Markets OTCPK - OTC Markets OTCPK Delayed price. Currency in USD
Add to watchlist
9.39-0.10 (-1.05%)
At close: 03:45PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.49
Open9.40
Bid9.35 x 40000
Ask9.39 x 40000
Day's range9.35 - 9.40
52-week range9.15 - 15.90
Volume2,637
Avg. volume376,901
Market cap16.991B
Beta (5Y monthly)0.30
PE ratio (TTM)156.50
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.46 (4.91%)
Ex-dividend date27 Mar 2024
1y target estN/A
  • Thomson Reuters StreetEvents

    Q4 2023 Taysha Gene Therapies Inc Earnings Call

    Q4 2023 Taysha Gene Therapies Inc Earnings Call

  • Reuters

    US FDA declines to approve Astellas' gastric cancer drug

    Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-party manufacturer. The FDA has not raised any concerns related to the clinical data, and is not requesting additional clinical studies, Astellas said. The company said it is working closely with the FDA and the third-party manufacturer to quickly resolve the regulator's feedback, adding that the decision does not affect any other Astellas product.

  • Reuters

    UPDATE 2-US FDA approves Astellas' combination therapy for bladder cancer

    The U.S. Food and Drug Administration on Friday approved Astellas Pharma's Padcev in combination with Merck's Keytruda for a type of bladder cancer. In April, FDA had granted accelerated approval to this combination for treating patients suffering from the disease that are ineligible for chemotherapy with the commonly used cancer drug, cisplatin. The FDA said on Friday the approval was based on a late-stage trial where the combination therapy met major efficacy outcomes of overall survival and progression-free survival, which is how long a patient lives without the disease getting worse after treatment.